Literature DB >> 17646667

Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.

Claudia D Baldus1, Peter Martus, Thomas Burmeister, Stefan Schwartz, Nicola Gökbuget, Clara D Bloomfield, Dieter Hoelzer, Eckhard Thiel, Wolf K Hofmann.   

Abstract

PURPOSE: Expression of the genes ERG (v-ets erythroblastosis virus E26 oncogene homolog) and BAALC (brain and acute leukemia, cytoplasmic) shows similarity during hematopoietic maturation and predicts outcome in acute myeloid leukemia. We hypothesized that like ERG, BAALC expression might be of prognostic significance in acute T-lymphoblastic leukemia (T-ALL) and that ERG and BAALC expression together would better identify the patient's risk profile. PATIENTS AND METHODS: ERG and BAALC mRNA expression were determined by real-time reverse transcriptase polymerase chain reaction in 153 adults with T-ALL. Patients were designated low or high ERG expressers and low or high BAALC expressers.
RESULTS: High BAALC expression correlated with a higher frequency of early T-ALL (P < .0001), CD34 positivity (P < .0001), coexpression of myeloid markers (P = .0001), and high ERG expression (P = .03). High BAALC compared with low BAALC patients had an inferior relapse-free survival (RFS; P = .0008) and overall survival (OS; P = .0001). In contrast, patients with low expression of both ERG and BAALC (representing 41% of all T-ALL patients) had the most favorable outcome (P < .0001; 4-year RFS: low ERG/low BAALC 81%; P < .0001; 4-year OS: low ERG/low BAALC 69%). On multivariable analysis, low ERG/low BAALC expression was of independent favorable prognostic significance (RFS, P = .001; OS, P = .003).
CONCLUSION: Low expression of both ERG and BAALC identifies T-ALL patients with a distinctly favorable long-term outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646667     DOI: 10.1200/JCO.2007.11.5253

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

1.  Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.

Authors:  Sandra Heesch; Nicola Goekbuget; Andrea Stroux; Jutta Ortiz Tanchez; Cornelia Schlee; Thomas Burmeister; Stefan Schwartz; Olga Blau; Ulrich Keilholz; Antonia Busse; Dieter Hoelzer; Eckhard Thiel; Wolf-Karsten Hofmann; Claudia D Baldus
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

2.  Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia.

Authors:  Yuho Najima; Kazuteru Ohashi; Machiko Kawamura; Yuji Onozuka; Toshikazu Yamaguchi; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2010-04-08       Impact factor: 2.490

3.  Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

4.  Poor Response to Standard Chemotherapy in Early T-precursor (ETP)-ALL: A Subtype of T-ALL Associated with Unfavourable Outcome: A Brief Report.

Authors:  Nida Iqbal; Atul Sharma; Vinod Raina; Lalit Kumar; Sameer Bakhshi; Rajive Kumar; Smeeta Gajendra
Journal:  Indian J Hematol Blood Transfus       Date:  2014-01-19       Impact factor: 0.900

5.  Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Authors:  Huining Kang; I-Ming Chen; Carla S Wilson; Edward J Bedrick; Richard C Harvey; Susan R Atlas; Meenakshi Devidas; Charles G Mullighan; Xuefei Wang; Maurice Murphy; Kerem Ar; Walker Wharton; Michael J Borowitz; W Paul Bowman; Deepa Bhojwani; William L Carroll; Bruce M Camitta; Gregory H Reaman; Malcolm A Smith; James R Downing; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

6.  Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.

Authors:  Vera Grossmann; Wolfgang Kern; Stefan Harbich; Tamara Alpermann; Sabine Jeromin; Susanne Schnittger; Claudia Haferlach; Torsten Haferlach; Alexander Kohlmann
Journal:  Haematologica       Date:  2011-08-09       Impact factor: 9.941

7.  mRNA overexpression of BAALC: A novel prognostic factor for pediatric acute lymphoblastic leukemia.

Authors:  Zahra Azizi; Soheila Rahgozar; Alireza Moafi; Mohammad Dabaghi; Motahareh Nadimi
Journal:  Biomed Rep       Date:  2015-02-26

8.  Role of BAALC Gene in Prognosis of Acute Lymphoblastic Leukemia in Egyptian Children.

Authors:  Adel A Hagag; Walid A Elshehaby; Nahd M Hablas; Mohamed M Abdelmageed; Amal Ezzat Abd El-Lateef
Journal:  Indian J Hematol Blood Transfus       Date:  2017-06-23       Impact factor: 0.900

9.  T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

Authors:  David I Marks; Elisabeth M Paietta; Anthony V Moorman; Susan M Richards; Georgina Buck; Gordon DeWald; Adolfo Ferrando; Adele K Fielding; Anthony H Goldstone; Rhett P Ketterling; Mark R Litzow; Selina M Luger; Andrew K McMillan; Marc R Mansour; Jacob M Rowe; Martin S Tallman; Hillard M Lazarus
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

10.  Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.

Authors:  Clara D Bloomfield; Albert de la Chapelle; Ann-Kathrin Eisfeld; Sebastian Schwind; Ravi Patel; Xiaomeng Huang; Ramasamy Santhanam; Christopher J Walker; Joseph Markowitz; Kevin W Hoag; Tiina M Jarvinen; Benjamin Leffel; Danilo Perrotti; William E Carson; Guido Marcucci
Journal:  Sci Signal       Date:  2014-04-15       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.